Abstract
The BIOFLOW V trial demonstrated a lower rate of target lesion failure (TLF) at 12 months in patients treated with the ultrathin strut, biodegradable polymer sirolimus-eluting stent (BP SES) compared to a thin strut, durable polymer everolimus-eluting stent (DP EES). The difference in TLF was driven
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
